Melatonin improves the restoration of endothelium-derived constricting factor signalling and inner diameter in the rat femoral artery after cessation of L-NAME treatment

Journal of Hypertension

Volumn 28, Issue SUPPL. 1, 2010, Pages

  Paulis, Ludovit ^a,b,c   Pechanova, Olga ^c,d   Zicha, Josef ^d   Liskova, Silvia ^b,d   Celec, Peter ^b   Mullerova, Martina ^b   Kollar, Jakub ^b   Behuliak, Michal ^b   Kunes, Jaroslav ^b,d   Adamcova, Michaela ^e   Simko, Fedor ^b,e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Physics and Informatics   (Slovakia)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

^d INSTITUTE OF MATHEMATICS   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

endothelium derived constricting factor; femoral artery; hypertension; L NAME; melatonin; mesenteric artery; nitric oxide; vessel myograph

Indexed keywords

ACETYLCHOLINE; ALKADIENE; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MELATONIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BLOOD PRESSURE MEASUREMENT; CAROTID ARTERY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENZYME ACTIVITY; FEMORAL ARTERY; GENE EXPRESSION; HEART LEFT VENTRICLE; HYPERTENSION; MALE; MESENTERIC ARTERY; MYOGRAPHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE;

EID: 77957267449     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000388490.28213.de     Document Type: Article

References (30)

1. Reiter RJ, Korkmaz A. Clinical aspects of melatonin. Saudi Med J 2008; 29:1537-1547.
2. Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res 2007; 42:319-322.
3. Simko F, Pechanova O, Pelouch V, Krajcirovicova K, Mullerova M, Bednarova K, et al. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J Hypertens 2009; 27 (Suppl 6):S5-S10.
4. Paulis L, Pechanova O, Zicha J, Krajcirovicova K, Barta A, Pelouch V, et al. Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats. J Hypertens 2009; 27 (Suppl. 6):S11-S16.
5. Paulis L, Pechanova O, Zicha J, Barta A,Gardlik R, Celec P, et al. Melatonin interactions with blood pressure and vascular function during L-NAMEinduced hypertension. J Pineal Res 2010; 48:102-108.
6. Paulis L, Simko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res 2007; 56:671-684.
7. Paulis L, Zicha J, Kunes J, Hojna S, Behuliak M, Celec P, et al. Regression of L-NAME-induced hypertension: the role of nitric oxide and endotheliumderived constricting factor. Hypertens Res 2008; 31:793-803.
8. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulinrequiring enzyme. Proc Natl Acad Sci U S A 1990; 87:682-685.
9. Kogure K, Watson R, Busto R, Abe K. Potentiation of lipid peroxides by ischemia in rat brain. Neurochem Res 1982; 7:437-453.
10. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977; 41:19-26.
11. Ribeiro MO, Antunes E, de-Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 1992; 20:298-303.
12. Pechanova O, Bernatova I, Pelouch V, Simko F. Protein remodeling of the heart in NO deficient hypertension: the effect of captopril. J Mol Cell Cardiol 1997; 29:3365-3374.
13. Simko F, Matuskova J, Luptak I, Krajcirovicova K, Kucharska J, Gvozdjakova A, et al. Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci 2004; 74:1211-1224.
14. Rossi MA, Colombini-Netto M. Chronic inhibition of NO synthesis per se promotes structural intimal remodeling of the rat aorta. J Hypertens 2001; 19:1567-1579.
15. Erren TC, Reiter RJ. Defining chronodisruption. J Pineal Res 2009; 46:245-247.
16. Simko F, Paulis L. Chronotherapy beyond blood pressure reduction? J Pineal Res 2008; 45:227-228.
17. Simko F, Pechanova O. Recent trends in hypertension treatment: perspectives fromanimal studies. J Hypertens 2009; 27 (Suppl. 6):S1-S4.
18. Reiter RJ, Tan DX, Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. J Hypertens 2009; 27 (Suppl. 6):S17-S20.
19. Paulis L, Simko F. LA419, a novel nitric oxide donor, prevents cardiac remodeling via the endothelial nitric oxide synthase pathway: NO donors as a means of antiremodeling. Hypertension 2007; 50:1009-1011.
20. Ruiz-Hurtado G, Fernández-Velasco M, Mourelle M, Delgado C. LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Hypertension 2007; 50:1049-1056.
21. Vanhoutte PM, Tang EH. Endothelium-dependent contractions: when a good guy turns bad!. J Physiol 2008; 586:5295-5304.
22. Kanner J, Harel S, Granit R. Nitric oxide, an inhibitor of lipid oxidation by lipoxygenase, cyclooxygenase and hemoglobin. Lipids 1992; 27:46-49.
23. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009; 15:43-50.
24. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997; 99:278-287.
25. Patel KP, Li YF, Hiroka Y. Role of nitric oxide in central sympathetic outflow. Exp Biol Med 2001; 226:814-824.
26. Usui M, Ichiki T, Katoh M, Egashira K, Takeshita A. Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension 1998; 32:527-533.
27. Sventek P, Li JS, Grove K, Deschepper CF, Schiffrin EL. Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats. Hypertension 1996; 27:49-55. (Pubitemid 26017680)
28. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res 1996; 33:181-194.
29. Elliott HL. Endothelial dysfunction in cardiovascular disease: risk factor, risk marker, or surrogate end point? J Cardiovasc Pharmacol 1998; 32 (Suppl. 3):S74-S77.
30. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998; 97:716-720.